Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
30 September 2013 |
Main ID: |
EUCTR2010-023623-26-IT |
Date of registration:
|
27/02/2012 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
The purpose of this study is to look at the safety, effectiveness, and tolerability of armodafinil when used with mood stabilizers in subjects with major depression associated with bipolar I disorder.
|
Scientific title:
|
A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder |
Date of first enrolment:
|
14/09/2011 |
Target sample size:
|
370 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-023623-26 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 2
|
Phase:
|
|
|
Countries of recruitment
|
Brazil
|
Bulgaria
|
Croatia
|
European Union
|
Finland
|
Germany
|
Hungary
|
India
|
Italy
|
Poland
|
South Africa
|
United States
| | | | |
Contacts
|
Name:
|
Start Up Group Global Regulatory
|
Address:
|
Via Cristoforo Colombo, 163
00147
Roma
Italy |
Telephone:
|
+39 0544 213422 |
Email:
|
paolo.collia@i3research.com |
Affiliation:
|
Ingenix Internation Italy (Srl) |
|
Name:
|
Start Up Group Global Regulatory
|
Address:
|
Via Cristoforo Colombo, 163
00147
Roma
Italy |
Telephone:
|
+39 0544 213422 |
Email:
|
paolo.collia@i3research.com |
Affiliation:
|
Ingenix Internation Italy (Srl) |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: (a)The patient has a diagnosis of bipolar I disorder according to the Diagnostic and Statistical Manual of Mental Disorders (DSM IV-TR) criteria (b) The investigator has established, by medical record documentation or by history from the patient and at least 1 reliable informant, that the patient has had at least 1 previous manic or mixed episode, which resulted in functional impairment and was treated (or should have been treated) with a mood stabilizer or antipsychotic medication. (c) The patient has had no more than 6 mood episodes in the last year. (d) The patient’s current major depressive episode must have started no less than 2 weeks and no more than 12 months prior to the screening visit. The current depressive episode must have begun after the patient’s current mood stabilizer regime began. Date of onset of the current depressive episode must be at least 8 weeks after resolution of any previous mood episode (ie, depressive, manic, hypomanic, or mixed episode). (e) The patient must have been taking 1 (or 2) of the following protocol allowed mood stabilizers: • lithium • valproic acid • lamotrigine • aripiprazole • olanzapine • risperidone • ziprasidone (only if taken in combination with lithium or valproic acid) The following criteria must also be met: • The mood stabilizer(s) must have been taken a minimum 4 weeks before the onset of the major depressive episode and still be taken at the time of the screening visit at dose or blood level considered appropriate for maintenance therapy by the patient’s physician. • The patient must continue to take the same mood stabilizer(s) during the screening period; no mood stabilizer may be added during the screening period. • The mood stabilizer(s) must be taken for a minimum of 8 weeks prior to the baseline visit. • The dosage of the mood stabilizer(s) must be stable for a minimum of 4 weeks prior to the baseline visit. Minimum required dosages and plasma concentrations, if applicable, and the lengths of time for these minimum requirements (4 or 8 weeks depending on the medication) are provided in the protocol. • The mood stabilizer(s) must be taken in an oral formulation, with the exception of risperidone, which can be either in an oral or long acting injection formulation. • The patient may be taking 2 protocol allowed mood stabilizers only if 1 of the drugs is lithium or valproic acid. (f) The patient has been on a stable dosage of all other permitted medications (with the exception of medication to be used on an as needed basis) for 2 weeks prior to the baseline visit. (g) The patient has a score of 13 or more on the QIDS-C16 at the screening and baseline visits. (NOTE: The QIDS C16 will be derived from specified items in the IDS C30.) (h) The patient has a CGI-S rating (for depression) of 4 (moderately ill) or higher at the screening visit and at the baseline visit. (i) The patient has a YMRS total score of 10 or less at the screening and baseline visits. (j) The patient has a YMRS score of 0 or 1 on items 1 through 3 at the screening and baseline visits. (k) Written informed consent is obtained. (l) The patient is a man or woman 18 through 65 years of age. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 370 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: (a)The patient has any Axis I disorder apart from bipolar I disorder that was the primary focus of treatment within 6 months of the screening visit or during the screening period. (b)The patient has psychotic symptoms or has had psychosis within 4 weeks of the screening visit or during the screening period. (c) The patient has current active suicidal ideation, is at imminent risk of self harm, or has a history of significant suicidal ideation or suicide attempt at any time in the past that causes concern at present; or, at any time during the screening period or at baseline has a score of 2 or more for item 18 on the IDS C30. (d) The patient has any history of homicidal ideation or significant aggression or currently has homicidal or significant aggressive ideation. (e) The patient has a history of an eating disorder or obsessive compulsive disorder (OCD) within 6 months of the screening visit or during the screening period. (f) The patient has a history of alcohol or substance abuse or dependence (with the exception of nicotine dependence) within 3 months of the screening visit or during the screening period. (g) The patient has borderline personality disorder or antisocial personality disorder. (h) The patient has any other Axis II disorder that could interfere with the conduct of the study. (i) The patient has a HAM A score of 17 or more at the baseline visit. (j) The patient has a history of any cutaneous drug reaction or drug hypersensitivity reaction, a history of any clinically significant hypersensitivity reaction, or a history of multiple clinically relevant allergies. (k) The patient has a past or present seizure disorder (except history of a single febrile seizure), or a history of clinically significant head trauma (eg, brain damage) or of brain surgery. (l) The patient has left ventricular hypertrophy or the patient has mitral valve prolapse and has experienced mitral valve prolapse syndrome. (m) The patient has human immunodeficiency virus (HIV). (n) The patient has any clinically significant uncontrolled medical condition, treated or untreated. (o) In the judgment of the investigator, the patient has any clinically significant deviation from normal in the physical examination. (p) The patient has 1 or more clinical laboratory test values outside the ranges specified in the protocol (q) The patient has any other clinically significant laboratory abnormality, without prior written approval by the medical monitor. (r) The patient has a positive urine drug screen (UDS) for anything other than cannabis.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
|
Major Depression associated with Bipolar Disorder I. MedDRA version: 14.1
Level: LLT
Classification code 10004911
Term: Bipolar affective disorder, depressed
System Organ Class: 10037175 - Psychiatric disorders
|
Intervention(s)
|
Trade Name: Armodafinil Pharmaceutical Form: Tablet INN or Proposed INN: NA CAS Number: 112111-43-0 Current Sponsor code: CEP-10953 Other descriptive name: NA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Primary end point(s): The primary efficacy measure and endpoint for this study is the IDS C30 assessed at all postbaseline visits.
|
Main Objective: The primary objective of the study is to determine whether armodafinil treatment, at a dosage of 150 mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adults with major depression associated with bipolar I disorder. Efficacy will be assessed by the mean change from baseline in the total score from the 30 Item Inventory of Depressive Symptomatology–Clinician Rated (IDS C30).
|
Secondary Objective: • To evaluate the efficacy of armodafinil treatment compared with placebo treatment as adjunctive therapy for adults who are experiencing a major depressive episode associated with bipolar I disorder, • To evaluate the change from baseline in the Clinical Global Impression of Severity (CGI-S) of illness rating for depression • to evaluate the efficacy of armodafinil treatment compared with placebo treatment on patient functioning as assessed by the Global Assessment of Functioning (GAF) Scale scores • To evaluate the safety and tolerability of armodafinil treatment
|
Timepoint(s) of evaluation of this end point: All postbaseline visits
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: • the IDS C30 will be assessed at weeks 1, 2, 4, 6, 7, and 8, or last postbaseline observation
• CGI-S for depression will be assessed at weeks 1, 2, 4, 6, 7, and 8, or last postbaseline observation
• GAF Scale will be assessed at weeks 4 and 8, or last postbaseline observation
|
Secondary end point(s): • IDS C30
• CGI-S for depression
• GAF Scale
|
Secondary ID(s)
|
2010-023623-26-HU
|
C10953/3073
|
Source(s) of Monetary Support
|
Cepaholn Inc.
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|